Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
648 stopped studies mapped to Myeloid Leukemia and descendants · 88% state a reason
Over the 648 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic… | Phase 2 | withdrawn | May 1, 2008 | University of Southern California | sponsor withdrew support | Other (stated, no rule matched) |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | Phase 1 | terminated | Mar 12, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients… | Phase 2 | terminated | Feb 18, 2013 | Karolinska University Hospital | Poor recruitment | Enrollment / accrual |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or… | Phase 1 | terminated | Apr 20, 2007 | Exelixis | Sponsor decision | Sponsor / business decision |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With… | Phase 1 | terminated | Dec 15, 2010 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous… | Phase 1 | terminated | Dec 12, 2011 | AstraZeneca | not stated | Not stated |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With… | Phase 2 | terminated | Sep 11, 2006 | Mirati Therapeutics Inc. | The Clinical Development Program for MGCD0103 is being re-evaluated | Other (stated, no rule matched) |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and… | Phase 1 / Phase 2 | terminated | Oct 18, 2010 | University Health Network, Toronto | not stated | Not stated |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive… | Phase 2 | terminated | Jan 31, 2012 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic… | Phase 1 | terminated | Dec 24, 2004 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01130688 | Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. | Phase 1 | terminated | May 26, 2010 | University of Massachusetts, Worcester | Lack of enrollment | Enrollment / accrual |
| NCT01188889 | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | Phase 1 / Phase 2 | withdrawn | Aug 26, 2010 | University of Michigan Rogel Cancer Center | Unable to obtain sufficient funding. | Funding |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With… | Phase 2 | terminated | Apr 25, 2008 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | Phase 1 | terminated | May 1, 2008 | New York Medical College | PI left institution | Investigator |
| NCT00943553 | A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction… | Phase 2 | withdrawn | Jul 22, 2009 | Eisai Inc. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT01065545 | The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia | Phase 1 | withdrawn | Feb 9, 2010 | Northwestern University | Due to funding issues. | Funding |
| NCT01203228 | Dose-reduced Versus Standard Conditioning in MDS/sAML(RICMAC) | Phase 3 | terminated | Sep 16, 2010 | European Society for Blood and Marrow Transplantation | not stated | Not stated |
| NCT01010373 | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and… | Phase 2 | suspended | Nov 10, 2009 | BioMAS Ltd | The sponsor is currently focusing on different indications | Other (stated, no rule matched) |
| NCT00500006 | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia… | Phase 1 | terminated | Jul 12, 2007 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00114959 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic… | Phase 2 | terminated | Jun 21, 2005 | ChemGenex Pharmaceuticals | Poor enrollment | Enrollment / accrual |
| NCT00907582 | ASCT for Relapsed APL After Molecular Remission | Phase 2 | terminated | May 22, 2009 | Shanghai Jiao Tong University School of Medicine | slow recruitment | Enrollment / accrual |
| NCT01650805 | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) | Phase 3 | terminated | Jul 26, 2012 | Ariad Pharmaceuticals | Study terminated based on evaluation of safety data. | Safety / toxicity |
| NCT02238522 | Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative… | Phase 1 | withdrawn | Sep 12, 2014 | Zenith Epigenetics | not stated | Not stated |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT00967512 | Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to… | Phase 2 | withdrawn | Aug 28, 2009 | Eleos, Inc. | Study Was Terminated due to lack of Funding. | Funding |
| NCT00593645 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | Phase 2 | terminated | Jan 15, 2008 | Washington University School of Medicine | toxicities were worse than expected | Safety / toxicity |
| NCT00184054 | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Competing studies | Other (stated, no rule matched) |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | Phase 2 | terminated | Dec 25, 2006 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01193400 | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age… | Phase 2 | terminated | Sep 1, 2010 | PETHEMA Foundation | not stated | Not stated |
| NCT01198054 | LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) | Phase 4 | terminated | Sep 9, 2010 | PETHEMA Foundation | not stated | Not stated |
| NCT01655875 | AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy…(BMTAMD3100) | Phase 1 | terminated | Aug 2, 2012 | Emory University | lack of patient enrollment | Enrollment / accrual |
| NCT01426334 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia… | Phase 1 | terminated | Aug 31, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00866346 | PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia… | Phase 1 | withdrawn | Mar 20, 2009 | M.D. Anderson Cancer Center | Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell production. | Enrollment / accrual |
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant… | Phase 1 / Phase 2 | withdrawn | Nov 8, 2006 | Genzyme, a Sanofi Company | not stated | Not stated |
| NCT01478074 | ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | Phase 1 | withdrawn | Nov 23, 2011 | Altor BioScience | The treatment planned was determined to be of low feasibility as no subject was found eligible and… | Enrollment / accrual |
| NCT00923234 | Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute…(AZALE) | Phase 1 | terminated | Jun 18, 2009 | Technische Universität Dresden | The primary objective has already been answered with the number of recruited patients. | Enrollment / accrual |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following…(WT-1) | Phase 1 | terminated | May 6, 2008 | Michael Morse, MD | low accrual | Enrollment / accrual |
| NCT00967525 | Intraosseous Infusion of Unrelated Cord Blood Grafts | N/A | terminated | Aug 28, 2009 | Emory University | poor enrollment | Enrollment / accrual |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted… | Phase 1 / Phase 2 | terminated | Dec 29, 2008 | Duke University | IND approval for naive T-cell depletion not obtained | Other (stated, no rule matched) |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing… | Phase 2 | terminated | Dec 28, 2011 | Texas Oncology Cancer Center | Insufficient accruals | Enrollment / accrual |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia… | Phase 1 / Phase 2 | withdrawn | Mar 1, 2006 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00985530 | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | Phase 1 | terminated | Sep 28, 2009 | Northwestern University | Supporting agency withdrew funding for study. | Funding |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic… | Phase 1 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 23, 2015source: clinicaltrials